A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP events, according to interim ...

The mean C max was 1.01 IU per milliliter (95% CI, 0.92 to 1.09) with recombinant ADAMTS13 and 0.19 IU per milliliter (95% CI, 0.15 to 0.22) with standard therapy (Table S8); in other words, on ...

ADAMTS13 is a plasma protein that, along with one’s platelets, plays an important role in the blood clotting process. 2 When concentrations of ADAMTS13 are lower, this shortage can lead to the ...

The multinational, open-label, controlled, randomized, crossover, phase 3 TAK-755 (NCT03393975) trial demonstrated superior efficacy and safety of recombinant ADAMTS13 as prophylaxis in patients ...

Ji, M., et al. (2024) ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury. A Randomized Clinical Trial. Journal of Clinical and Translational Hepatology ...

OSAKA, Japan& CAMBRIDGE, Mass.---- Takeda today announced that the European Commission approved ADZYNMA ® for the treatment of ADAMTS13 deficiency in children and adult patients with congenital ...

About Recombinant ADAMTS13 (rADAMTS13) rADAMTS13 is the first and only recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (ADAMTS13) enzyme replacement therapy ...

DOI 10.14218/JCTH.2024.00233 Article Title ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury Article Publication Date 22-Dec-2024 ...

Caption Hepatic platelet accumulation in PA-ILI was confirmed in both patients and mice. Deficiency of ADAMTS13 plays a critical role in platelet accumulation in PA-ILI, suggesting that ADAMTS13 ...

In patients with immune thrombotic thrombocytopenic purpura (iTTP), autoantibodies against the metalloprotease ADAMTS13 lead to catastrophic microvascular thrombosis. However, the potential benefit ...